Fisetin Inhibits Osteoclast Differentiation via Downregulation of p38 and c-Fos-NFATc1 Signaling Pathways
Figure 1
Fisetin inhibits RANKL-mediated osteoclast differentiation. (a) Structure of fisetin. (b) BMM cells were cultured for 4 days in the presence of RANKL (5 ng/mL) and M-CSF (30 ng/mL) with the vehicle (DMSO) or fisetin. Multinucleated osteoclasts were visualized to red-colored giant cells by TRAP staining. (c) Total TRAP-positive multinucleated osteoclasts (TRAP + MNCs; left graph) and TRAP + MNCs with more than 3 nuclei (; right graph) were counted. **; *** (versus “the control”). (d) TRAP activity was measured. ### (versus “the negative control”). **; *** (versus “the positive control”). (e) After pretreatment with the vehicle (DMSO) or fisetin (5 μM) for 1 h, BMMs were treated with RANKL (5 ng/mL) for the indicated number of days, and then mRNA expression levels were analyzed by real-time PCR. *; **; *** (versus “the vehicle control”). (f) Effect of fisetin on the viability of BMMs was evaluated by CCK-8 assay.